Treatment of an elderly patient with acute myelocytic leukemia transformed from myelodysplastic syndrome with decitabine in ultra-low dosage combining with transfusion of autologous cytokineinduced killer cells: A case report and review of literature

Medical Journal of Chinese People's Liberation Army

Volumn 39, Issue 4, 2014, Pages 315-319

  Yang, Bo ^a   Cai, Li Li ^a   Wang, Hai Tao ^a   Zhu, Hong Li ^a   Chi, Xiao Hua ^b   Yu, Rui Li ^a   Yang, Yang ^a   Ran, Hai Hong ^a   Xin, Li Jun ^a   Yao, Shan Qian ^a   Lu, Xue Chun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Laboratory Medicine General Hospital of PLA ^*  (China)

Author keywords

Acute; Aged; Cytokine induced killer (CIK) cells; Decitabine; Leukemia; Myelocytic; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW DISEASE; CASE REPORT; CELL THERAPY; CYTOKINE INDUCED KILLER CELL; DEATH; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKOCYTOSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PNEUMONIA; VERY ELDERLY;

EID: 84933512233     PISSN: 05777402     EISSN: None     Source Type: Journal    
DOI: 10.11855/j.issn.0577-7402.2014.04.13     Document Type: Article

References (29)

1. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients[ J]. J Clin Oncol, 2007, 25(14): 1908-1915.
2. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediateor high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[ J]. J Clin Oncol, 2011, 29(15): 1987-1996.
3. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy[ J]. Haematologica, 2012, 97(3): 393-401.
4. Yang B, Lu XC, Yu RL, et al. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial[ J]. Hematol Oncol, 2012, 30(3): 115-122.
5. Liu Y, Bao EN, Yang B, et al. Clinical study of autologous cytokine induced killer cell infusion treating for elderly patients, with myelodysplastic syndrome[ J]. J Exp Hematol, 2011, 19(3): 787-792.
6. Wang Y, Bo J, Dai HR, et al. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo[ J]. Exp Hematol, 2013, 41(3): 241-252.
7. Lu XC, Yang B, Zhu HL, et al. Cytokine-induced killer plus IL-2 for elderly patients with a hematological malignancy[ J]. Med J Chin PLA, 2010, 35(10): 1270-1272.
8. Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity[ J]. Blood, 2011, 118(12): 3301-3310.
9. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents[J]. Ann Intern Med, 1985, 103(2): 195-200.
10. Pagano L, Mele L, Casorelli I, et al. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study[J]. Haematologica, 2000, 85(12): 1327-1329.
11. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study[ J]. Blood, 1997, 89(9): 3323-3329.
12. Li TT, Sun XD, Dong Z, et al. Comparison of molecular biology, immunological characteristics and clinical efficacy in patients with acute myelogenous leukemia with or without FLT3-ITD gene mutation[J]. Med J Chin PLA, 2013, 38(6): 501-505.
13. Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome[ J]. Cancer, 2006, 106(5): 1090-1098.
14. Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase- III intergroup study[ J]. Ann Hematol, 1992, 65(4): 162-168.
15. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group[ J]. J Clin Oncol, 2009, 27(1): 61-69.
16. Ziogas DC, Voulgarelis M, Zintzaras E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly[ J]. Clin Ther, 2011, 33(3): 254-279.
17. Ma YY, Zhou SJ, Chen FY, et al. Induction effects of decitabine in combination with valproic acid sodium on apoptosis of myeloma cells and its underlying mechanism[ J]. Med J Chin PLA, 2013, 38(10): 837-841.
18. Lv HR, Deng Q, Li YM. Effect of Decitabine combined with atra on proliferation and differentiation of hl-60 cells[ J]. Tianjin Med J, 2013, 41(2): 154-157.
19. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[ J]. J Clin Oncol, 2012, 30(21): 2670-2677.
20. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study[ J]. Cancer, 2006, 106(8): 1794-1803.
21. Bordoni RE, Feinberg BA, Gilmore JW, et al. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice[ J]. Clin Lymphoma Myeloma Leuk, 2011, 11(4): 350-354.
22. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia[ J]. J Clin Oncol, 2010, 28(4): 556-561.
23. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine[ J]. Proc Natl Acad Sci USA, 2010, 107(16): 7473-7478.
24. Wang LX, Mei ZY, Zhou JH, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses[ J]. PLoS One, 2013, 8(5): e62924.
25. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine[ J]. Oncotarget, 2013, 4(10): 1729-1736.
26. Tsai HC, Li H, Van Neste L, Cai Y, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells[ J]. Cancer Cell, 2012, 21(3): 430-446.
27. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas[ J]. J Immunother, 2008, 31(1): 63-71.
28. Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma[ J]. World J Gastroenterol, 2004, 10(8): 1146-1151.
29. Märten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations[ J]. J Immunother, 2001, 24(6): 502-510.